nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
|
Nair, Gonasagrie |
|
|
10 |
12 |
p. e779-e789 |
artikel |
2 |
ART and cardiovascular-disease risk in people with HIV
|
Malvestutto, Carlos |
|
|
10 |
12 |
p. e760-e761 |
artikel |
3 |
Correction to Lancet HIV 2023; 10: e424–26
|
|
|
|
10 |
12 |
p. e762 |
artikel |
4 |
Correction to Lancet HIV 2023; 10: e244–53
|
|
|
|
10 |
12 |
p. e762 |
artikel |
5 |
Correction to Lancet HIV 2023; 10: e385–93
|
|
|
|
10 |
12 |
p. e762 |
artikel |
6 |
Correction to Lancet HIV 2018; 5: e696–705
|
|
|
|
10 |
12 |
p. e762 |
artikel |
7 |
Correction to Lancet HIV 2023; 10: e375–84
|
|
|
|
10 |
12 |
p. e762 |
artikel |
8 |
Effect of implementation strategies on pre-exposure prophylaxis persistence among female sex workers in South Africa: an interrupted time series study
|
Rao, Amrita |
|
|
10 |
12 |
p. e807-e815 |
artikel |
9 |
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
|
Landovitz, Raphael J |
|
|
10 |
12 |
p. e767-e778 |
artikel |
10 |
Highlights of the 19th European AIDS Conference
|
Gonzalez-Lopez, Adrian |
|
|
10 |
12 |
p. e763 |
artikel |
11 |
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment
|
Sullivan, Ann K |
|
|
10 |
12 |
p. e790-e806 |
artikel |
12 |
Long-acting cabotegravir PrEP: a time for cautious optimism
|
Griffin, David WJ |
|
|
10 |
12 |
p. e756-e757 |
artikel |
13 |
LVCT Health: implementing PrEP in Kenya
|
Ligami, Christabel |
|
|
10 |
12 |
p. e766 |
artikel |
14 |
Making the most of a fertile PrEP landscape
|
The Lancet HIV, |
|
|
10 |
12 |
p. e755 |
artikel |
15 |
Planning for PrEP: are national surveillance data sufficient?
|
Rutstein, Sarah E |
|
|
10 |
12 |
p. e759-e760 |
artikel |
16 |
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions
|
Mayer, Kenneth H |
|
|
10 |
12 |
p. e816-e824 |
artikel |
17 |
PrEParing for choice in a new era of HIV prevention
|
Graybill, Lauren A |
|
|
10 |
12 |
p. e757-e758 |
artikel |
18 |
PrEP empowering female sex workers in Kenya
|
Ligami, Christabel |
|
|
10 |
12 |
p. e764-e765 |
artikel |
19 |
Programme science: a route to effective coverage and population-level impact for HIV and sexually transmitted infection prevention
|
McClarty, Leigh M |
|
|
10 |
12 |
p. e825-e834 |
artikel |